

NOVO NORDISK A S
Form 6-K
March 01, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

February 29, 2016

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 29 February 2016 - On 3 February 2016, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.

Under the programme initiated 3 February 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 3 February 2016 to 27 April 2016.

Since the announcement as of 22 February 2016, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,310,000		763,780,137
22 February 2016	175,000	347.90	60,882,780
23 February 2016	165,000	352.22	58,116,597
24 February 2016	175,000	343.97	60,195,328
25 February 2016	170,000	349.68	59,445,005
26 February 2016	170,000	355.38	60,414,753
Accumulated under the programme	3,165,000		1,062,834,599

With the transactions stated above, Novo Nordisk owns a total of 57,788,102 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 26 February 2016, Novo Nordisk has repurchased a total of 3,165,000 B shares equal to a transaction value of DKK 1,062,834,599.

Further information

Media:

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com

Investors:

Peter Hugrefte Ankensen +45 3075 9085 phak@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com

Kasper Veje +45 3079 8519 kpvj@novonordisk.com

		Telephone:	Internet:
Novo Nordisk A/S	Novo Allé		www.novonordisk.com
Investor Relations	2880 Bagsværd	+45 4444 8888	CVR no:
	Denmark		24 25 67 90

Company announcement No 19 / 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: February 29, 2016

Lars Rebien Sørensen,

Chief Executive Officer